PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 2829507-5 1987 In slice preparations of this region NPY reduces forskolin and phorbolester-induced cAMP accumulation. Cyclic AMP 84-88 neuropeptide Y Homo sapiens 37-40 2480920-7 1989 Although NPY attenuated forskolin-induced accumulation of cyclic AMP, forskolin- and 3-isobutyl-1-methyl-xanthine-induced alterations in intracellular cyclic AMP did not affect the NPY-induced [Ca2+]i rise. Cyclic AMP 58-68 neuropeptide Y Homo sapiens 9-12 2480920-8 1989 These results suggest that NPY increases [Ca2+]i by a pertussis toxin-sensitive GTP binding protein-involved mechanism which is not mediated by the intracellular messengers such as Ins(1,4,5)P3 and cyclic AMP. Cyclic AMP 198-208 neuropeptide Y Homo sapiens 27-30 3202164-3 1988 NPY inhibited adenosine 3,5"-cyclic monophosphate (cAMP) accumulation in HEL cells with a 50% effective concentration (EC50) of 3 nM. Cyclic AMP 14-49 neuropeptide Y Homo sapiens 0-3 3202164-3 1988 NPY inhibited adenosine 3,5"-cyclic monophosphate (cAMP) accumulation in HEL cells with a 50% effective concentration (EC50) of 3 nM. Cyclic AMP 51-55 neuropeptide Y Homo sapiens 0-3 2544451-0 1989 Neuropeptide Y inhibits vasoactive intestinal peptide- and dopamine-induced cyclic AMP formation in human Ewing"s sarcoma WE-68 cells. Cyclic AMP 76-86 neuropeptide Y Homo sapiens 0-14 2544451-1 1989 Neuropeptide Y (NPY) regulation of intracellular cyclic AMP accumulation was studied in human Ewing"s sarcoma cell line, WE-68. Cyclic AMP 49-59 neuropeptide Y Homo sapiens 0-14 2544451-1 1989 Neuropeptide Y (NPY) regulation of intracellular cyclic AMP accumulation was studied in human Ewing"s sarcoma cell line, WE-68. Cyclic AMP 49-59 neuropeptide Y Homo sapiens 16-19 2544451-2 1989 NPY inhibited vasoactive intestinal peptide (VIP)- and dopamine-stimulated but not basal cyclic AMP formation. Cyclic AMP 89-99 neuropeptide Y Homo sapiens 0-3 2544451-5 1989 It is concluded that NPY attenuates agonist-stimulated cyclic AMP formation in Ewing"s sarcoma WE-68 cells, and may do so via the inhibitory guanine nucleotide regulatory protein of adenylate cyclase. Cyclic AMP 55-65 neuropeptide Y Homo sapiens 21-24 2557407-3 1989 The effect of NPY in conjunction with isoproterenol (ISO) on cyclic AMP (cAMP) accumulation and noradrenaline (NA) on melatonin synthesis was investigated using in vitro techniques. Cyclic AMP 61-71 neuropeptide Y Homo sapiens 14-17 2996299-0 1985 Neuropeptide Y is a potent inhibitor of cyclic AMP accumulation in feline cerebral blood vessels. Cyclic AMP 40-50 neuropeptide Y Homo sapiens 0-14 2455156-8 1987 This interaction may in part take place at the level of the Ni protein, since NPY (300 nM) inhibited cyclic AMP (cAMP) accumulation in slices of the dorsomedial medulla. Cyclic AMP 101-111 neuropeptide Y Homo sapiens 78-81 2455156-8 1987 This interaction may in part take place at the level of the Ni protein, since NPY (300 nM) inhibited cyclic AMP (cAMP) accumulation in slices of the dorsomedial medulla. Cyclic AMP 113-117 neuropeptide Y Homo sapiens 78-81 32029445-5 2020 In contrast, neuropeptide Y (NPY) reduced VIP-evoked cAMP increases, CFTR activation, and Cl-/HCO3 - secretion. Cyclic AMP 53-57 neuropeptide Y Homo sapiens 13-27 32029445-5 2020 In contrast, neuropeptide Y (NPY) reduced VIP-evoked cAMP increases, CFTR activation, and Cl-/HCO3 - secretion. Cyclic AMP 53-57 neuropeptide Y Homo sapiens 29-32 20332211-0 2010 Neuropeptide Y Y5 receptor promotes cell growth through extracellular signal-regulated kinase signaling and cyclic AMP inhibition in a human breast cancer cell line. Cyclic AMP 108-118 neuropeptide Y Homo sapiens 0-14 23358240-10 2013 Conversely, activating the exchange protein activated by cAMP (Epac) with 8CPT-2Me-cAMP blocked the effect of L-P NPY on NMDA-mediated eEPSCs, but not on GABAA-mediated eIPSCs. Cyclic AMP 57-61 neuropeptide Y Homo sapiens 114-117 21272667-6 2011 This process stabilizes the peptide in alpha-helix conformation, abrogates its degradation by dipeptidyl peptidase-4 and potentiates NPY-induced inhibition of cAMP elaboration in SK-N-MC cells. Cyclic AMP 159-163 neuropeptide Y Homo sapiens 133-136 28737807-9 2017 Our results show that Tyr36 nitration destabilizes the alpha-helix conformation of the peptide, and counteracts NPY-induced inhibition of cAMP accumulation in SK-N-MC cells. Cyclic AMP 138-142 neuropeptide Y Homo sapiens 112-115 20332211-8 2010 NPY inhibited forskolin-stimulated cyclic AMP accumulation with an IC(50) value of 52 pmol/L. Cyclic AMP 35-45 neuropeptide Y Homo sapiens 0-3 19371763-5 2009 Functional analysis of NPY receptor activation indicated that the Y1/Y4/Y5 receptor agonist [Leu31, Pro34] significantly induced cAMP accumulation in the GT1-7 neurons. Cyclic AMP 129-133 neuropeptide Y Homo sapiens 23-26 19622099-6 2009 The inhibition of eIPSC amplitude by [Leu,Pro]NPY or NPY(3-36) was stable for approximately 30 min following the initial increase in cAMP levels. Cyclic AMP 133-137 neuropeptide Y Homo sapiens 46-49 19622099-6 2009 The inhibition of eIPSC amplitude by [Leu,Pro]NPY or NPY(3-36) was stable for approximately 30 min following the initial increase in cAMP levels. Cyclic AMP 133-137 neuropeptide Y Homo sapiens 53-56 16339211-9 2006 NPY treatment reduced forskolin-stimulated cAMP accumulation only in PC3 cells and did not change intracellular calcium concentration in any PCa cell line. Cyclic AMP 43-47 neuropeptide Y Homo sapiens 0-3 16585197-6 2006 Chronic estrogen treatment enhanced NPY-mediated inhibition of cAMP accumulation by 4-fold and caused a significant increase in Y1R mRNA expression through ERalpha. Cyclic AMP 63-67 neuropeptide Y Homo sapiens 36-39 15365223-3 2004 In euthymic Li-treated bipolar patients, there was an inverse correlation between plasma NPY-LI levels and intracellular cAMP in prostaglandin E1-stimulated platelets. Cyclic AMP 121-125 neuropeptide Y Homo sapiens 89-92 14753296-5 2003 In both cell lines binding of NPY induced signal transduction, which was monitored as reduction of forskolin-induced cAMP production in an ELISA. Cyclic AMP 117-121 neuropeptide Y Homo sapiens 30-33 11287092-7 2001 Part of the response was sensitive to pertussis toxin (PTX) under conditions where the toxin totally abolished the NPY-mediated effects on cAMP. Cyclic AMP 139-143 neuropeptide Y Homo sapiens 115-118 11282111-2 2001 In the human intestinal epithelial cell line HT29cl.19A, it has been previously shown that neuropeptide Y inhibits the electrophysiological phenomena related to Cl(-) secretion, when induced by elevation of cAMP via forskolin. Cyclic AMP 207-211 neuropeptide Y Homo sapiens 91-105 11814622-2 2002 The Y(1) receptor agonist, [Leu(31),Pro(34)]-NPY, inhibited forskolin-stimulated cAMP production which was insensitive to thapsigargin or the CaM kinase II inhibitor, KN-93. Cyclic AMP 81-85 neuropeptide Y Homo sapiens 45-48 11814622-9 2002 These findings suggest that the NPY Y(1) receptor induces the expression of CRE containing target genes through the CaM kinase-CREB pathway, and inhibits CRE containing genes when cellular cAMP levels are elevated. Cyclic AMP 189-193 neuropeptide Y Homo sapiens 32-35 11358498-9 2001 Inhibition of cAMP-accumulation of selected peptides with replacements within position 20-23 of NPY showed preserved agonistic properties. Cyclic AMP 14-18 neuropeptide Y Homo sapiens 96-99 11287092-2 2001 We have recently characterized a human glioblastoma cell line, LN319, that expresses exclusively NPY Y2 receptors and have demonstrated that NPY triggers transient decreases in cAMP and increases in intracellular calcium responses. Cyclic AMP 177-181 neuropeptide Y Homo sapiens 141-144 11287093-1 2001 In HEC-1B cells transfected with human Y(5) neuropeptide Y (NPY) receptors (but not in non-transfected cells) NPY inhibited forskolin-stimulated cAMP accumulation in a pertussis toxin-sensitive manner (-log EC(50) 8.88 +/- 0.25). Cyclic AMP 145-149 neuropeptide Y Homo sapiens 60-63 11287093-1 2001 In HEC-1B cells transfected with human Y(5) neuropeptide Y (NPY) receptors (but not in non-transfected cells) NPY inhibited forskolin-stimulated cAMP accumulation in a pertussis toxin-sensitive manner (-log EC(50) 8.88 +/- 0.25). Cyclic AMP 145-149 neuropeptide Y Homo sapiens 110-113 11287093-4 2001 We conclude that at least upon expression in HEC-1B cells the signal transduction of Y(5) NPY receptors is limited to inhibition of cAMP accumulation. Cyclic AMP 132-136 neuropeptide Y Homo sapiens 90-93 9669502-2 1998 In this study, the activity of these peptides at each of the cloned neuropeptide Y receptor subtypes is determined in radioligand binding assays and in functional assays (inhibition of forskolin-stimulated cAMP formation). Cyclic AMP 206-210 neuropeptide Y Homo sapiens 68-82 10526260-6 1999 NPY mRNA levels were also induced by protein kinase modulators (Bu)(2)cAMP and staurosporine in the cultures (P < 0.05). Cyclic AMP 70-74 neuropeptide Y Homo sapiens 0-3 11762347-6 2001 The activation of these receptors by NPY resulted in a reduction of forskolin-induced cAMP accumulation and an increase of [Ca2+]i. Cyclic AMP 86-90 neuropeptide Y Homo sapiens 37-40 10369484-5 1999 Forskolin (1 microM) stimulated cyclic AMP accumulation in porcine ear artery segments in the presence of 0.1 microM U46619 and 1 mM isobutylmethylxanthine (IBMX), NPY (0.1 microM) inhibited this response by 40%, but had no effect on basal levels of cyclic AMP. Cyclic AMP 32-42 neuropeptide Y Homo sapiens 164-167 10369484-6 1999 An enhanced response to 0.1 microM NPY was also obtained after pre-contraction with 0.1 microM U46619 and relaxation with either SNP (28.9+/-5.7%, n = 14), or dibutyryl cyclic AMP (21.2+/-4.6%, n = 14). Cyclic AMP 169-179 neuropeptide Y Homo sapiens 35-38 10027771-10 1999 Finally, NPY significantly inhibited the forskolin-induced cAMP production in smooth muscle but not in endothelial cell cultures. Cyclic AMP 59-63 neuropeptide Y Homo sapiens 9-12 9795117-8 1998 NPY appears to block (+)DPAT-induced phase shifts by preventing increases in cyclic AMP. Cyclic AMP 77-87 neuropeptide Y Homo sapiens 0-3 9802424-0 1998 NPY upregulates genes containing cyclic AMP response element in human neuroblastoma cell lines bearing Y1 and Y2 receptors: involvement of CREB. Cyclic AMP 33-43 neuropeptide Y Homo sapiens 0-3 9802424-1 1998 Four NPY receptor subtypes have been cloned, and shown to be coupled to both Ca2+ and cAMP. Cyclic AMP 86-90 neuropeptide Y Homo sapiens 5-8 9667962-11 1998 Antagonist activity of these BIs was confirmed by measuring the ability of selected compounds to reverse NPY-induced forskolin-stimulated cyclic AMP. Cyclic AMP 138-148 neuropeptide Y Homo sapiens 105-108 9688998-9 1998 NPY antagonized beta-agonist-induced accumulation of cAMP. Cyclic AMP 53-57 neuropeptide Y Homo sapiens 0-3 9382934-9 1998 From this study we conclude that NPY inhibits cAMP-stimulated as well as Ca2+-stimulated secretion via a reduction in the apical Cl- and basolateral K+ conductance. Cyclic AMP 46-50 neuropeptide Y Homo sapiens 33-36 9277359-9 1997 Pretreatment with SNP significantly attenuated NPY-induced inhibition of cAMP formation in SK-N-MC cells but had no effect on CHP cells. Cyclic AMP 73-77 neuropeptide Y Homo sapiens 47-50 9165460-4 1997 NPY receptor function in the absence of or following RA treatment was determined by the ability of various concentrations of NPY to attenuate the forskolin-stimulated accumulation of intracellular cAMP. Cyclic AMP 197-201 neuropeptide Y Homo sapiens 0-3 9165460-4 1997 NPY receptor function in the absence of or following RA treatment was determined by the ability of various concentrations of NPY to attenuate the forskolin-stimulated accumulation of intracellular cAMP. Cyclic AMP 197-201 neuropeptide Y Homo sapiens 125-128 7790925-8 1995 Activation of the protein kinase A pathway with the cAMP analog dibutyryl cAMP, or the adenylyl cyclase activator forskolin, produced a concentration-dependent, sustained stimulation of NPY secretion; maximal stimulation resulted in decreased cellular NPY content. Cyclic AMP 52-56 neuropeptide Y Homo sapiens 186-189 9020878-5 1997 Both basal and forskolin-stimulated cAMP levels were inhibited by 100 nM NPY and by 100 nM NPY(13-36), a selective agonist of the NPY Y2-receptor subtype. Cyclic AMP 36-40 neuropeptide Y Homo sapiens 73-76 9020878-5 1997 Both basal and forskolin-stimulated cAMP levels were inhibited by 100 nM NPY and by 100 nM NPY(13-36), a selective agonist of the NPY Y2-receptor subtype. Cyclic AMP 36-40 neuropeptide Y Homo sapiens 91-94 8959744-4 1996 This peptide did not exhibit any agonist activity at Y1 receptors, and exhibited comparable potencies in antagonizing the effects of NPY on the synthesis of cAMP and mobilization of [Ca2+]i in HEL cells. Cyclic AMP 157-161 neuropeptide Y Homo sapiens 133-136 7790925-8 1995 Activation of the protein kinase A pathway with the cAMP analog dibutyryl cAMP, or the adenylyl cyclase activator forskolin, produced a concentration-dependent, sustained stimulation of NPY secretion; maximal stimulation resulted in decreased cellular NPY content. Cyclic AMP 74-78 neuropeptide Y Homo sapiens 186-189 7716277-3 1994 These 2 antibodies block the binding of NPY to its receptor as well as the NPY-induced inhibition of cAMP accumulation caused in SK-N-MC cells by forskolin. Cyclic AMP 101-105 neuropeptide Y Homo sapiens 40-43 7538948-0 1995 Effect of cAMP elevation on the NPY gene transcription. Cyclic AMP 10-14 neuropeptide Y Homo sapiens 32-35 7716277-3 1994 These 2 antibodies block the binding of NPY to its receptor as well as the NPY-induced inhibition of cAMP accumulation caused in SK-N-MC cells by forskolin. Cyclic AMP 101-105 neuropeptide Y Homo sapiens 75-78 7716277-6 1994 NPY03 and NPY04 inhibit the binding of NPY only at very high concentrations and have a weak effect on cAMP response to NPY. Cyclic AMP 102-106 neuropeptide Y Homo sapiens 0-3 7716277-6 1994 NPY03 and NPY04 inhibit the binding of NPY only at very high concentrations and have a weak effect on cAMP response to NPY. Cyclic AMP 102-106 neuropeptide Y Homo sapiens 10-13 8132619-1 1994 Neuropeptide Y (NPY) attenuated angiotensin II (AII)-or bradykinin (BK)-induced Ca2+ release from intracellular stores and inhibited forskolin-stimulated cAMP accumulation and omega-conotoxin-sensitive high K(+)-induced Ca2+ influx in the human neuroblastoma cell line SMS-KAN. All three NPY actions were mediated via Y2 receptors. Cyclic AMP 154-158 neuropeptide Y Homo sapiens 0-14 7977753-3 1994 PYY and [Leu31,Pro34]NPY inhibited forskolin-stimulated adenosine 3",5"-cyclic monophosphate production 63% and 48%, respectively, with a half-maximal inhibitory concentration between 0.1 and 1.0 nM. Cyclic AMP 56-92 neuropeptide Y Homo sapiens 21-24 8203544-4 1994 When applied together on HTG cells, NPY and NE induced an increase of intracellular cAMP, a discrete sustained increase of basal intracellular Ca2+, and a long-lasting inhibition of secretion. Cyclic AMP 84-88 neuropeptide Y Homo sapiens 36-39 8132619-1 1994 Neuropeptide Y (NPY) attenuated angiotensin II (AII)-or bradykinin (BK)-induced Ca2+ release from intracellular stores and inhibited forskolin-stimulated cAMP accumulation and omega-conotoxin-sensitive high K(+)-induced Ca2+ influx in the human neuroblastoma cell line SMS-KAN. All three NPY actions were mediated via Y2 receptors. Cyclic AMP 154-158 neuropeptide Y Homo sapiens 16-19 8228323-5 1993 On the other hand, neuropeptide Y (NPY) showed an inhibitory effect on forskolin-induced cyclic AMP accumulation in keratinocytes. Cyclic AMP 89-99 neuropeptide Y Homo sapiens 19-33 8132547-9 1994 Pertussis toxin did not affect the NPY-stimulated [Ca2+]i increase, although it abolished the NPY-dependent inhibition of cAMP production. Cyclic AMP 122-126 neuropeptide Y Homo sapiens 94-97 8228323-5 1993 On the other hand, neuropeptide Y (NPY) showed an inhibitory effect on forskolin-induced cyclic AMP accumulation in keratinocytes. Cyclic AMP 89-99 neuropeptide Y Homo sapiens 35-38 1329739-2 1992 NPY induced an increase in intracellular calcium ion concentration ([Ca2+]i) and inhibition of forskolin-stimulated cyclic AMP accumulation, which were mediated through Y1 receptors. Cyclic AMP 116-126 neuropeptide Y Homo sapiens 0-3 1329739-4 1992 PMA had no effect on [125I]BH-NPY binding in SK-N-MC cells and hardly inhibited the endothelin-1-induced increase in [Ca2+]i. Pertussis toxin also inhibited the NPY-induced [Ca2+]i increase 30-fold more effectively than the NPY-mediated inhibition of cyclic AMP accumulation. Cyclic AMP 251-261 neuropeptide Y Homo sapiens 161-164 1329739-4 1992 PMA had no effect on [125I]BH-NPY binding in SK-N-MC cells and hardly inhibited the endothelin-1-induced increase in [Ca2+]i. Pertussis toxin also inhibited the NPY-induced [Ca2+]i increase 30-fold more effectively than the NPY-mediated inhibition of cyclic AMP accumulation. Cyclic AMP 251-261 neuropeptide Y Homo sapiens 161-164 1317848-9 1992 Moreover, in the Y1 receptor-transfected COS1 cells, but not in type 1 angiotensin II receptor-transfected control cells, NPY and PYY accelerated 45Ca2+ influx and inhibited forskolin-stimulated cAMP accumulation, both phenomena being characteristic of the mammalian Y1 receptor. Cyclic AMP 195-199 neuropeptide Y Homo sapiens 122-125 1320624-4 1992 In the Ewing"s sarcoma cell lines NPY provoked inhibition of forskolin-stimulated cyclic AMP formation by up to 98%. Cyclic AMP 82-92 neuropeptide Y Homo sapiens 34-37 1314499-1 1992 Peptide YY (PYY) and neuropeptide Y (NPY) inhibit agonist-induced adenosine 3",5"-cyclic monophosphate (cAMP) production and pepsinogen secretion from chief cells. Cyclic AMP 66-102 neuropeptide Y Homo sapiens 21-35 1314499-1 1992 Peptide YY (PYY) and neuropeptide Y (NPY) inhibit agonist-induced adenosine 3",5"-cyclic monophosphate (cAMP) production and pepsinogen secretion from chief cells. Cyclic AMP 66-102 neuropeptide Y Homo sapiens 37-40 1314499-1 1992 Peptide YY (PYY) and neuropeptide Y (NPY) inhibit agonist-induced adenosine 3",5"-cyclic monophosphate (cAMP) production and pepsinogen secretion from chief cells. Cyclic AMP 104-108 neuropeptide Y Homo sapiens 21-35 1314499-1 1992 Peptide YY (PYY) and neuropeptide Y (NPY) inhibit agonist-induced adenosine 3",5"-cyclic monophosphate (cAMP) production and pepsinogen secretion from chief cells. Cyclic AMP 104-108 neuropeptide Y Homo sapiens 37-40 1314499-9 1992 In guinea pig chief cells, PYY and NPY modulate cAMP-mediated pepsinogen secretion by interacting with specific high-affinity Y2 receptors. Cyclic AMP 48-52 neuropeptide Y Homo sapiens 35-38 1320624-5 1992 Pertussis toxin alleviated the cyclic-AMP-inhibitory response to NPY. Cyclic AMP 31-41 neuropeptide Y Homo sapiens 65-68 1320624-7 1992 The ability of NPY and analogues to inhibit cyclic AMP accumulation paralleled their potencies in displacing radioligand binding. Cyclic AMP 44-54 neuropeptide Y Homo sapiens 15-18 1320624-9 1992 These results demonstrate that conventional Ewing"s sarcoma cells possess Gi-protein-coupled NPY receptors of the Y1 type, which upon interaction with NPY, PYY, and PP mediate inhibition of cyclic AMP generation. Cyclic AMP 190-200 neuropeptide Y Homo sapiens 93-96 1320624-9 1992 These results demonstrate that conventional Ewing"s sarcoma cells possess Gi-protein-coupled NPY receptors of the Y1 type, which upon interaction with NPY, PYY, and PP mediate inhibition of cyclic AMP generation. Cyclic AMP 190-200 neuropeptide Y Homo sapiens 151-154 1310131-8 1992 A common dual coupling mechanism of NPY/PYY receptors, i.e. to reduction of cAMP and to Ca2+ elevation, is therefore suggested to exist, although both phenomena could not be demonstrated in every cell type. Cyclic AMP 76-80 neuropeptide Y Homo sapiens 36-39 2159234-5 1990 Exposure of intact cells to NPY caused a concentration-dependent pertussis toxin-sensitive inhibition of forskolin-stimulated cellular adenosine 3",5"-cyclic monophosphate (cAMP) accumulation [50% effective concentration (EC50) = 0.4 nM]. Cyclic AMP 135-171 neuropeptide Y Homo sapiens 28-31 1650417-6 1991 Finally, the effect of human NPY on intraplatelet cAMP was measured. Cyclic AMP 50-54 neuropeptide Y Homo sapiens 29-32 2164571-4 1990 NPY inhibited cyclic AMP accumulation in SK-N-MC cells stimulated by isoproterenol, dopamine, vasoactive intestinal peptide, cholera toxin, and forskolin. Cyclic AMP 14-24 neuropeptide Y Homo sapiens 0-3 2164571-5 1990 NPY inhibited isoproterenol-stimulated cyclic AMP production in a dose-dependent manner, with half-maximal inhibition at 0.5 nM NPY. Cyclic AMP 39-49 neuropeptide Y Homo sapiens 0-3 2164571-5 1990 NPY inhibited isoproterenol-stimulated cyclic AMP production in a dose-dependent manner, with half-maximal inhibition at 0.5 nM NPY. Cyclic AMP 39-49 neuropeptide Y Homo sapiens 128-131 2164571-8 1990 Pertussis toxin treatment of the cells completely blocked the ability of NPY to inhibit cyclic AMP production and adenylate cyclase activity. Cyclic AMP 88-98 neuropeptide Y Homo sapiens 73-76 2159800-5 1990 The concentration range (low microM) over which neuropeptide Y increases the polarization of diphenylhexatriene in cell membranes is similar to the range in which it inhibits isoproterenol-stimulated cAMP accumulation. Cyclic AMP 200-204 neuropeptide Y Homo sapiens 48-62 2159800-7 1990 These data suggest that neuropeptide Y contains an amphipathic alpha-helical region which interacts with lipids in much the same way as the amphipathic alpha-helical regions of the plasma apolipoproteins and that the inhibition of isoproterenol-stimulated cAMP accumulation at low microM concentrations of peptide may be the result of an alteration in the cell membrane bilayer structure. Cyclic AMP 256-260 neuropeptide Y Homo sapiens 24-38 1647673-3 1991 PYY and NPY, but not pancreatic polypeptide, starting at nanomolar concentrations, caused a 40-50% inhibition of secretin-, vasoactive intestinal polypeptide-, prostaglandin E2-, and forskolin-induced increases in chief cell adenosine 3",5"-cyclic monophosphate (cAMP) content and pepsinogen secretion. Cyclic AMP 225-261 neuropeptide Y Homo sapiens 8-11 1647673-3 1991 PYY and NPY, but not pancreatic polypeptide, starting at nanomolar concentrations, caused a 40-50% inhibition of secretin-, vasoactive intestinal polypeptide-, prostaglandin E2-, and forskolin-induced increases in chief cell adenosine 3",5"-cyclic monophosphate (cAMP) content and pepsinogen secretion. Cyclic AMP 263-267 neuropeptide Y Homo sapiens 8-11 1647673-7 1991 In gastric chief cells, PYY and NPY attenuate the stimulatory effects of secretagogues whose actions are mediated by changes in cellular levels of cAMP. Cyclic AMP 147-151 neuropeptide Y Homo sapiens 32-35 2170410-7 1990 In parallel studies, NPY alone had no detectable effect on cellular cAMP or cGMP content; however, NPY potently inhibited forskolin-stimulated cAMP accumulation (IC50 = 0.03 nM) through a pertussis toxin-sensitive pathway. Cyclic AMP 143-147 neuropeptide Y Homo sapiens 99-102 2167504-0 1990 Actions of neuropeptide Y on basal, cyclic AMP-induced and neurally evoked ion transport in porcine distal jejunum. Cyclic AMP 36-46 neuropeptide Y Homo sapiens 11-25 2159234-5 1990 Exposure of intact cells to NPY caused a concentration-dependent pertussis toxin-sensitive inhibition of forskolin-stimulated cellular adenosine 3",5"-cyclic monophosphate (cAMP) accumulation [50% effective concentration (EC50) = 0.4 nM]. Cyclic AMP 173-177 neuropeptide Y Homo sapiens 28-31 2153577-6 1990 Y1 receptor stimulation, by both NPY and [Leu31,Pro34]NPY, also inhibited the forskolin-stimulated cAMP production with an EC50 of 3.5 nM. Cyclic AMP 99-103 neuropeptide Y Homo sapiens 33-36 2153577-6 1990 Y1 receptor stimulation, by both NPY and [Leu31,Pro34]NPY, also inhibited the forskolin-stimulated cAMP production with an EC50 of 3.5 nM. Cyclic AMP 99-103 neuropeptide Y Homo sapiens 54-57 2170253-5 1990 Specific receptor mechanisms for NPY exist at both the pre- and postjunctional levels; a large amidated C-terminal portion of NPY is necessary for receptor binding, inhibition of cyclic AMP formation and vasoconstrictor effects. Cyclic AMP 179-189 neuropeptide Y Homo sapiens 126-129